IPP Bureau
Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars
By IPP Bureau - September 17, 2025
Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
By IPP Bureau - September 16, 2025
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav
By IPP Bureau - September 16, 2025
The inspection was carried out between May 26, 2025 and May 31, 2025
CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR
By IPP Bureau - September 16, 2025
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Syensqo introduces medical-grade Amodel PPA for medical devicess
By IPP Bureau - September 16, 2025
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
By IPP Bureau - September 16, 2025
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Zen Multispeciality Hospital bags CII WR Health Innovation award 2025
By IPP Bureau - September 16, 2025
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Nanyang Biologics, NVIDIA, HPE & Equinix to launch AI drug discovery platform
By IPP Bureau - September 16, 2025
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter secures seed investment to scale drug discovery knowledge platform
By IPP Bureau - September 16, 2025
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
By IPP Bureau - September 16, 2025
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
By IPP Bureau - September 16, 2025
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares
By IPP Bureau - September 16, 2025
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
By IPP Bureau - September 16, 2025
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
GAIASO appoints Dr. Tracey Brown as CEO
By IPP Bureau - September 16, 2025
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
